Objective To assess the prognostic and clinicopathological characteristics of CD147 in human bladder cancer.
INTRODUCTION
Bladder cancer is the ninth most common cancer worldwide [1] . It was estimated that 76,960 new cases (4.6% of all new cancer cases) and 16,390 deaths would occur due to bladder cancer in the United States in 2016 [2] . High-grade invasive bladder cancer usually has a worse prognosis than low-grade superficial tumors. Unfortunately, approximately 30% newly diagnosed bladder cancer patients have invasive cancer [3] , and 10-20% of superficial tumors will progress to invasive diseases. Thus, prediction of the progression of bladder cancer in certain patients remains a major challenge. Invasive cystoscopy is the most common method to detect suspected bladder cancer, because of the low sensitivity of other diagnostic tests, like urine cytology [3] . Bladder cancer has different biological characteristics, and patients with the same disease stage may have divergent clinical courses and different outcomes after receiving the same therapy [4] . Therefore, there is an urgent need for more sensitive and specific biomarkers that provide www.impactjournals.com/oncotarget/ Oncotarget, 2017, Vol. 8, (No. 37), pp: 62573-62588 Meta-Analysis reliable information for tumor diagnosis, and elucidate the biological behavior of these tumors. This may allow more precise assessment of and better-targeted effective therapy for bladder cancer. A number of biomarkers such as survivin [5] , fascin [6] , MCT1, MCT4, and CD147 [7] were found to be involved in the development and progression of bladder cancer. Among these biomarkers, CD147, or extracellular matrix metalloproteinase inducer (EMMPRIN), is a transmembrane protein that acts as an important mediator of tumor cell invasion [8] . It is overexpressed in various tumors such as breast, lung, oral, esophageal, laryngeal, and renal cancers [9] [10] [11] [12] [13] [14] . In vitro suppression of CD147 has been shown to inhibit the proliferation, migration, and invasion of T24 bladder cancer cells [15] . There are also a number of studies on CD147 expression profiles in bladder cancer patients, which indicate that CD147 may serve as a prognostic biomarker. However, some of these study results are controversial. For example, some studies showed that the positive expression of CD147 predicts poor overall survival (OS) [4, 7, [15] [16] [17] [18] , while Afonso et al. [16] and Choi et al. [7] declared no significance of positive or negative expression of CD147. Furthermore, Afonso et al. [16] and Han et al. [19] claimed that CD147 predicts poor disease specific survival (DSS), which contradicts the results of Hemdan et al. [17] . Some studies showed a significant association between CD147 over-expression and tumor stage [7, 20] , while others disputed this [21] . The same conflict was also seen in the studies of lymphatic invasion status [7, 22] , TNM stage [21, 23] , and recurrence status [18, 24] . Therefore, we conducted this meta-analysis to quantitatively evaluate the relationship between CD147 and clinicopathological features and survival of bladder cancer patients.
RESULTS

Literature search and characteristics of included studies
A total of 147 studies were identified, of which 63 were excluded because of duplication. After reading the titles and abstracts, a further 50 studies were excluded. The remaining 34 full text studies were carefully reviewed (animal studies [n=3]; review and meta-analysis [n=5]; no control group [n=2]). Finally, 24 studies [4, 7, were included for quantitative analysis (Figure 1 ).
The characteristics of these studies are summarized in Table 1 . A total of 2493 patients, with or without bladder cancer, are included in 24 studies mostly in China (sixteen studies conducted in China [15, 18, 19, [21] [22] [23] [24] [25] [28] [29] [30] [31] [32] [33] [34] [35] , one from Portugal [16] , one from Sweden [17] , one from Korea [7] , one from Egypt [20] , one from India [26] , one from Germany [27], one from Denmark [4] , and one from Japan [36] ). 8 studies [4, 7, [15] [16] [17] [18] [19] 22] with 9 datasets (the study by Hemdan et al. [17] had 2 datasets, grouped based on differences in treatment) are included in the survival analysis ( Table 2 ). The pathological types of bladder cancer were transitional cell carcinoma, squamous cell carcinoma, and adenocarcinoma. The studies were published between 1993 and 2015. Immunohistochemistry (IHC) was used to detect the expression of CD147 in all studies, while reverse transcriptase polymerase chain reaction, Western blot, array analysis, immunoelectron microscopy, and nucleic acid in situ hybridization were also used in six studies [4, 21, 22, 26, 27, 36] .
Qualitative assessment
The study quality was assessed using the NewcastleOttawa quality assessment scale (NOS), generating scores ranging from 7 to 8 (with a mean of 7.25), where a higher value (0-9) indicates better methodology. The results of the quality assessment are shown in Table 1 (Figure 2A, 2B ).
CD147 expression and DSS
Three studies [17, 19, 22] (Figure 2C, 2D ).
CD147 expression and DFS
Zhong et al. [18] and Afonso et al. [16] performed a univariate analysis for disease recurrence-free survival (DFS); however only Zhong et al. [18] 
CD147 and recurrence
Five studies [7, 18, 23, 24, 35] Figure 3A ).
CD147 expression in bladder cancer and bladder embryonic tissues
Two studies [28, 30] reported the positive expression of CD147 in bladder cancer tissues and bladder embryonic tissues, including 147 bladder cancer tissues and 20 bladder embryonic tissues. Without heterogeneity (P=0.603, I
2 =0%), the fixed-effects model showed that positive expression of CD147 in bladder cancer tissues was higher than in bladder embryonic tissues (OR=46.78, 95% CI= [6.17, 354 .65], P=0.0002) ( Figure 3B ). Streptavidin-perosidase (SP), Labeled-perosidase (LP), Avidin-biotin complex (ABC), Streptavidin-avidin-biotin complex (SABC) A:Positive cell percentage A1: scored 0 (0 %), 1 (<5 %), 2 (5-50 %), 3 (>50 %). A2: scored 0-10. A3: scored 1 (<25 %), 2 (25-50%), 3 (51-75%), 4 (>75%). A4: scored 0 (<10%), 1 (10-50 %), 2 (>50%). A5: scored 0 (≤5%), 1 (6-25%), 2 (26-50%), 3 (≥50%) B: Staining intensity B1: scored 0 (absence of staining), 1 (weak staining), 2 (moderate staining), 3 (strong staining). B2: scored 0-10. B3: scored 0 (absence of staining), 1 (pale brown), 2 (dark brown) www.impactjournals.com/oncotarget
CD147 expression in bladder cancer and normal bladder tissues
Nine studies [23-25, 28, 30, 31, 33-35] investigated the positive expression of CD147 in bladder cancer tissues and normal bladder tissues, including 531 bladder cancer tissues and 113 normal bladder tissues. Fixed-effects model showed that CD147 positive expression was greater in bladder cancer tissues (OR=37.99, 95% CI= [16.97, 85 .03], P<0.00001), without heterogeneity (P=0.73, I 2 =0%) ( Figure 3C ).
CD147 in bladder cancer and para-carcinoma tissues
Three studies [21, 22, 29] reported the expression of CD147 in bladder cancer tissues and para-carcinoma tissues, including 215 bladder cancer tissues and 42 para-carcinoma tissues. Fixed-effects model showed a higher rate of CD147 expression in the bladder cancer group (OR=59.50, 95% CI= [13.75, 257 .42], P<0.00001), without heterogeneity (P=0.94, I
2 =0%) ( Figure 3D ). Correlation of CD147 expression with clinicopathological parameters
CD147 and clinical stage
Clinical stage is an international standard for tumor staging. Stages are grouped into two categories, with TNM I-II having a better prognosis than TNM III-IV. The association between CD147 and clinical stage was investigated in two studies [19, 28] , which showed that CD147 expression in the TNM III-IV stage group was greater than that in TNM I-II stage group, with fixed-effects model (OR=73.89, 95% CI=[9.61, 568.15], P<0.0001) and without heterogeneity (P=1.00, I 2 =0%) ( Figure 4A ).
Correlation of CD147 with invasive depth
Invasive depth also named tumor stage, from pTa to pT4, indicates deeper infiltration of the bladder wall. The association between CD147 and invasive depth was 
CD147 expression and lymph node metastasis
Six studies [7, 15, 16, 22, 32, 35] reported the relationship between CD147 expression and lymph node metastasis of bladder cancer. Heterogeneity was observed in the analysis (P=0.006, I 2 =69%), and therefore, a randomeffects model was used. The results showed no association between CD147 expression and lymph node metastasis (OR=2.20, 95% CI=[0.82, 5.89], P=0.12) ( Figure 4C ).
CD147 and histological differentiation
Histologically, bladder cancer is categorized into low, moderate, and high differentiations. Fourteen studies [7, 15, Figure 4D ).
CD147 and sex
Five studies [7, 15, 18, 22, 29] Figure 4E ).
Sensitivity analysis and publication bias
A sensitivity analysis was performed to evaluate the reliability of the results. While multiple datasets were available, sensitivity was tested by excluding studies one by one. Except in the case of Lymph node metastasis vs. No lymph node metastasis, all analyses were stable. To test for publication bias, we use Egger's test. All P values were higher than 0.05, indicating no publication bias. In summary, the results were stable and reliable (Table 4, Figure 5 and Figure 6 ).
DISCUSSION
CD147, also known as EMMPRIN, is a transmembrane glycoprotein in the immunoglobulin superfamily. It is highly expressed in many types of malignant tumors, including 
Overall survival (OS), Disease specific survival(DSS), Disease recurrence-free survival (DFS), univariate analysis (U), Streptavidin-perosidase (SP), multivariate analysis (M). Non-SP includes labeled-perosidase (LP), avidin-biotin complex (ABC), streptavidin-avidin-biotin complex (SABC) and EnVision.
Others are based on staining intensity or both staining intensity and positive cell percentage.
OS (U), OS (M), DSS (U), DSS (M) and DFS (U) used HR as effect size and recurrence used OR as effect size.
breast carcinoma, gastrointestinal cancer, prostate cancer, and bladder cancer, and plays a significant role in tumor proliferation, invasion, metastasis, as well as in many other processes in tumorigenesis and tumor development [37] [38] [39] .
In the current meta-analysis, we pooled 25 datasets from 24 studies [4, 7, [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] and demonstrated a notable association between CD147 expression and patients with bladder cancer. According to our results, CD147 expression is closely associated with prognostic and clinicopathological characteristics of bladder cancer. Irrespective of whether the parameter tested was OS, DSS, or DFS, univariate analysis showed that patients with higher CD147 positive expression were more likely to have worse prognosis. Multivariate analysis for OS and DFS gave the same result. However, regarding multivariate analysis for DSS, our results showed no difference between CD147 positive and negative expression groups. Besides this, our results also indicated that CD147 positive expression is correlated with higher rates of recurrence. Our findings relating to survival rate were in accordance with those of other studies comparing CD147 positive and negative expression with OS, DSS, or DFS in breast, ovarian, and gastrointestinal cancers [40] [41] [42] . Results of subgroup analysis based on IHC and cut-off values were in accordance with our main results.
Furthermore, CD147 expression is associated with the response to chemotherapy for bladder cancer, and Misra et al. [43] demonstrated that CD147 enhances tumor growth and chemoresistance via the phosphatidylinositol 3-kinase (PI3K)/Akt pathway in a hyaluronan-dependent manner. Als et al. [4] found that the response rates in patients with CD147-negative and CD147-positive tumors were 74% and 39% respectively, with an odds ratio of 4.41 (95% CI= [1.91-10.1] ). In addition, by silencing CD147 via RNA interference In vitro, Afonso et al. [16] showed a lower cisplatin IC 50 for bladder cancer (from 24.11 μg/ ml to 7.42 μg/ml). That is, the downregulation of CD147 sensitizes bladder cancer cells to chemotherapy.
As CD147 can promote the activity and expression of MCT-1 and MCT-4, forming complexes on the membrane to transport lactic acid produced by anaerobic tumor glycolysis, its expression may be increased in tumor tissues [42, 44] . As such, we investigated CD147 expression in different bladder tissues. The results showed that CD147 expression in bladder cancer tissues is greater than that in non-cancer tissues including embryonic bladder tissues, normal bladder tissues, and para-carcinoma tissues.
Next, we compared the expression of CD147 in relation to recurrence, clinical stages, invasive depth, lymph node metastasis, histological differentiation, and sex, to explore the correlation of CD147 expression with these clinicopathological parameters. In summary, CD147 expression is strongly associated with more advanced clinical stages, greater invasive depth, and poorer histological differentiation. However, CD147 expression is not correlated with lymph node metastasis or sex. As CD147 can facilitate the secretion of matrix metalloproteinase (MMP)-1, MMP-3, MMP-9, and membrane type-1 MMP, it may bring about the degradation of the basement membrane and extracellular matrix. This is one of the major mechanisms of its promotion of tumor metastasis [37, 45] . The meta-analyses of Huang et al. [41] and Peng et al. [46] also indicated that CD147 expression is associated with lymph node metastasis in gastrointestinal and prostate cancers. However, we found no association between CD147 positive expression and lymph node metastasis. However, when we excluded the study of Gao et al. [32] , this result was reversed. Therefore, further qualified studies are needed to assess the relationship between CD147 and lymph node metastasis in bladder cancer.
Besides the immunohistochemistry of CD147 protein levels analyzed in this study, other researches are available. Using Western blotting, Xue et al. [15] showed higher CD147 expression in bladder cancer cell lines T24, SCaBER, 5637, BIU-87, and J82 than in the normal urothelial cell line SV-HUC-1. In particular, the T24 and SCaBER cell lines had the highest CD147 protein levels. Bhagirath et al. [26] compared the serum concentration of CD147 in bladder cancer patients and healthy people by enzyme-linked immunosorbent assay and found a significant increase in CD147 levels in the serum samples of bladder cancer patients. Similarly, Li et al. [21] demonstrated higher CD147 mRNA levels in bladder transitional cell carcinoma (59.7%) than in normal bladder tissue (0%), but found no difference with clinical stage (r=0.048, P=0.698) or histological differentiation (r=0.222, P=0.071). Min et al. [22] also found upregulation of CD147 in bladder cancer at both mRNA and protein levels (mRNA: bladder cancer tissues 0.967±0.133, paracarcinoma tissues 0.223±0.096; protein: bladder cancer tissues 0.766±0.103, paracarcinoma tissues 0.165±0.055).
To our knowledge, this meta-analysis is the first to report the relationship between CD147 and bladder cancer. We analyzed 24 high-quality studies (NOS≥7 points) with significant results. Meanwhile, some limitations need to be acknowledged. First, our analysis is based upon published studies found in the literature, but we failed to obtain any unpublished data. Second, patients we included are mostly from China, which limits the universality of our results. Third, different studies used different criteria for CD147 expression, with different follow-up times. This may result in some bias. Nevertheless, we conducted subgroup analyses based on IHC and cut-off values, and this indicates that our results were reliable.
In this meta-analysis, we demonstrated that CD147 expression is increased in bladder cancer tissues compared with non-cancer tissues. This is strongly correlated with poorer OS, DSS, and DFS; recurrence; advanced clinical stages; greater invasive depth; and poorer histological differentiation. However, it was not correlated with lymph node metastasis or sex. In summary, CD147 could be an important diagnostic and prognostic biomarker for bladder cancer. 
